News Releases

Philadelphia Eagles owner Jeffrey Lurie today announced a $1 million contribution to Penn Medicine to establish the COVID-19 Immunology Defense Fund, laying the foundation for the world’s foremost experts to fight the novel coronavirus pandemic.

As part of a pledge to coronavirus medical relief efforts, NBA All-Star Joel Embiid of the Philadelphia 76ers, along with the team’s managing partner, Josh Harris, and co-managing partner, David Blitzer, today announced a combined contribution of $1.3 million to Penn Medicine, establishing a funding campaign for COVID-19 antibody testing of front line health care workers.

A new trial led by the Perelman School of Medicine at the University of Pennsylvania will evaluate whether the drug hydroxychloroquine (HCQ) can benefit people infected with COVID-19.

The Center for Research on Coronaviruses and Other Emerging Pathogens aims to advance research efforts and support development of new therapies, vaccines.

A new analysis challenges the longstanding notion that tuberculous infection is a life-long infection that could strike at any time and cause tuberculosis (TB). Based on a review of clinical studies, researchers from the Perelman School of Medicine at the University of Pennsylvania and colleagues show that people who test positive with immunologic TB skin or blood tests rarely develop TB.

The candidate vaccine, described in Nature Communications this week, elicited a strong antibody response to a structure on the surface of flu viruses, called the hemagglutinin (HA) stalk. It protected mice from infection by various flu strains.

The genome sequences of ape parasites related to Plasmodium vivax (P. vivax), the main source of mosquito-borne malaria outside Africa, provide insights on the origin and early evolution of the human parasite. This finding could have implications for better comprehending and eradicating malaria infection worldwide.

Protein fragments, called amyloid fibrils, in human semen significantly increase Ebola virus infection and protect the virus against harsh environmental conditions such as heat and dehydration.